AI data trainer roles have moved from obscure contractor gigs to a visible career path with clear pay bands and defined ...

For the last three years, the world has obsessed over generative AI that can write and create. By the end of 2026, we'll see ...

By transferring temporal knowledge from complex time-series models to a compact model through knowledge distillation and attention mechanisms, the ...

For more than a century, photographers have had to choose which part of a scene should be tack sharp and which parts would ...

A Kapwing study reveals that over 20 percent of videos recommended to new YouTube users are low-quality, AI-generated content ...

Dr. Nassir Marrouche is director of the Heart and Vascular Institute at Tulane University with a subspecialty in ...

The non-conference season is over, and without going too far out on a limb, I feel comfortable saying that no one is wildly ...

Instagram's new 'Your Algorithm' tool lets you control your Reels feed in real time. The app now gives you power to customize what videos you see.

Gilead Sciences, Inc. GILD announced that the investigational single-tablet regimen of bictegravir and lenacapavir for the treatment of HIV met the primary endpoint in the late-stage ARTISTRY-2 study.

– Positive Phase 3 Results from Both ARTISTRY-2 and ARTISTRY-1 Trials will Form the Basis of Regulatory Submissions – FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses ...